@article{Miossec_2017, title={Anti-Cytokine Biotherapies and Inflammatory Joint Diseases}, volume={4}, url={https://www.mbmj.org/index.php/ijms/article/view/57}, DOI={10.15342/ijms.v4is.141}, abstractNote={<p>Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis represent the most frequent inflammatory arthritis where the three cytokines TNF, IL-6, and IL-17 contribute to the clinical expression and the consequences on a joint structure. Each cytokine has a specific mode of action that explains differences in therapeutic indications. TNF inhibitors showed impressive clinical results first in rheumatoid arthritis. These results were then extended to psoriatic arthritis, and ankylosing spondylitis.<br />IL-6 inhibitors are registered only for rheumatoid arthritis and those of IL-17 for psoriatic arthritis, and ankylosing spondylitis. The wider use of these new molecules has required the definition of recommendations to better define their field of action and to prevent their side effects, first from infections.</p>}, journal={Integrative Journal of Medical Sciences}, author={Miossec, Pierre}, year={2017}, month={May}, pages={51–54} }